TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

CHIESI

RespiratoryCardiovascularDermatology
Big Pharma

CHIESI is a major pharmaceutical company focused on Respiratory, Cardiovascular, Dermatology. Key products include KENGREAL.

1988
Since
15
Drugs
-
Trials
5
Approved (2yr)

Key Drugs

KENGREAL
cangrelor
Cardiovascular
P2Y12 2 indications · 2015
FILSUVEZ
birch triterpenes
1 indications · 2023
BETHKIS
tobramycin
Respiratory
1 indications · 2012
MYCAPSSA
octreotide acetate
Somatostatin receptor 1 indications · 2020

Recent Activity

FERRIPROX 2025-03-26
Labeling
FERRIPROX 2025-03-26
Labeling
FERRIPROX 2025-03-26
Labeling
CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER 2025-02-21
Labeling
MYCAPSSA 2024-07-11
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Respiratory 79%
1 drugs Phase 3: 16 Phase 2: 14 Phase 1: 26
Cardiovascular 18%
4 drugs Phase 3: 1
Dermatology 3%
0 drugs Phase 3: 1
Gastroenterology 1%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

APOTHECON specialty
Dermatology, Cardiovascular, Gastroenterology, Respiratory
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology
COREPHARMA other
Cardiovascular, Respiratory, Gastroenterology, Dermatology
Pfizer big-pharma
Dermatology, Gastroenterology
LEDERLE big-pharma
Cardiovascular, Dermatology, Respiratory